GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoviricides Inc (FRA:NV3P) » Definitions » Inventories, Other

Nanoviricides (FRA:NV3P) Inventories, Other : €0.00 Mil (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Nanoviricides Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Nanoviricides's other inventories for the quarter that ended in Dec. 2024 was €0.00 Mil.


Nanoviricides Inventories, Other Historical Data

The historical data trend for Nanoviricides's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoviricides Inventories, Other Chart

Nanoviricides Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nanoviricides Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Nanoviricides Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Nanoviricides Business Description

Traded in Other Exchanges
Address
1 Controls Drive, Shelton, CT, USA, 06484
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Nanoviricides Headlines

No Headlines